Strong clinical benefit assessments by the Institute for Clinical and Economic Review’s California Technology Assessment Forum for both bluebird bio’s lovo-cel and Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s exa-cel gene therapies for sickle cell disease presage smooth approval decisions by the US FDA for the two gene therapies at the end of 2023.
If FDA acts positively on each application in December (December 8 for exa-cel and December 20 for lovo-cel), that should...








